open access

Vol 71, No 1 (2020)
Clinical vignette
Submitted: 2019-08-27
Accepted: 2019-09-19
Early publication date: 2019-09-30
Get Citation

Worsening of unrecognized tumour-induced osteomalacia with inadvertent use of recombinant human parathyroid hormone

Rimesh Pal1, Kanhaiya Agrawal1, Setu Gupta2, Anil Bhansali1, Arunanshu Behera3, Sanjay Kumar Bhadada1
DOI: 10.5603/EP.a2019.0045
·
Pubmed: 31566250
·
Endokrynol Pol 2020;71(1):102-103.
Affiliations
  1. Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
  2. Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
  3. Department of General Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India

open access

Vol 71, No 1 (2020)
Clinical Vignette
Submitted: 2019-08-27
Accepted: 2019-09-19
Early publication date: 2019-09-30

Abstract

Not required for Clinical Vignette.

Abstract

Not required for Clinical Vignette.

Get Citation

Keywords

tumour-induced osteomalacia; teriparatide; hypophosphataemia; fragility fracture

About this article
Title

Worsening of unrecognized tumour-induced osteomalacia with inadvertent use of recombinant human parathyroid hormone

Journal

Endokrynologia Polska

Issue

Vol 71, No 1 (2020)

Article type

Clinical vignette

Pages

102-103

Early publication date

2019-09-30

Page views

2588

Article views/downloads

591

DOI

10.5603/EP.a2019.0045

Pubmed

31566250

Bibliographic record

Endokrynol Pol 2020;71(1):102-103.

Keywords

tumour-induced osteomalacia
teriparatide
hypophosphataemia
fragility fracture

Authors

Rimesh Pal
Kanhaiya Agrawal
Setu Gupta
Anil Bhansali
Arunanshu Behera
Sanjay Kumar Bhadada

References (7)
  1. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007; 18(6): 1637–1647.
  2. Pal R, Bhadada SK, Shingare A, et al. Tumor-induced osteomalacia: experience from three tertiary care centres In India. Endocr Connect. 2019 [Epub ahead of print].
  3. Minisola S, Peacock M, Fukumoto S, et al. Tumour-induced osteomalacia. Nat Rev Dis Primers. 2017; 3: 17044.
  4. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19(3): 429–435.
  5. Blau JE, Collins MT. The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord. 2015; 16(2): 165–174.
  6. Lanske B, Razzaque MS. Molecular interactions of FGF23 and PTH in phosphate regulation. Kidney Int. 2014; 86(6): 1072–1074.
  7. Hajime M, Okada Y, Mori H, et al. A case of teriparatide-induced severe hypophosphatemia and hypercalcemia. J Bone Miner Metab. 2014; 32(5): 601–604.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl